Skip to main content

HAE Haemonetics Corporation

Healthcare

121.11

Close 10/14

P/E
59.4
P/B
6.6
52W 48.62 123.77
Loading candles…

Is Haemonetics Corporation a buy? Fundamentals and valuation first

As of 2026-10-14

Quality: Good, Momentum: Strong, Risk / liquidity: Good; Valuation: Pricey.

Valuation Pricey Free-cash-flow yield is Good, but Price / book is Expensive.
TTM P/E 59.37 86th percentile Expensive
Price / book 6.58 87th percentile Expensive
Free-cash-flow yield (%) 5.29 67th percentile Good
Quality Good All 3 indicators are Good.
ROE, TTM (%) 11.5 68th percentile Good
Operating margin, TTM (%) 18.18 70th percentile Good
FCF margin, TTM (%) 21.54 79th percentile Good
Growth Neutral All 2 indicators are Average.
Revenue growth, TTM YoY (%) 0.44 36th percentile Average
Diluted EPS growth, TTM YoY (%) -37.61 40th percentile Average
Momentum Strong All 2 indicators are Top.
60-day return (%) 55.13 98th percentile Top
240-day return (%) 144.96 98th percentile Top
Risk / liquidity Good 20-day dollar volume is Top, but 60-day annualized volatility is Average.
20-day dollar volume 81,293,882 86th percentile Top
60-day annualized volatility (%) 53.2 57th percentile Average

Haemonetics Corporation (HAE) today

2 quant signals active · As of 2026-10-14

Win rate and excess are historical post-trigger stats vs the market. Click a signal for its full definition and samples; history does not predict future results.

Haemonetics Corporation (HAE) peers and tracking

Watchlist

This page refreshes daily after the close. Add Haemonetics Corporation to your watchlist to track signal changes on your next visit.

Haemonetics Corporation (HAE) quant signal backtests

Signals active now

Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.

52-week adjusted-price high

Active

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

18 historical occurrences (since 2017-02-03)
Average forward return after 52-week adjusted-price high。20-day: Win 58.8%, Sample 17, Median +2.46%, Excess +0.75%, Beat mkt rate 52.9%；60-day: Win 56.2%, Sample 16, Median +5.32%, Excess +3.48%, Beat mkt rate 56.2%；120-day: Win 56.2%, Sample 16, Median +1.59%, Excess +2.8%, Beat mkt rate 43.8%

120 days after: historical avg +9.2%

20-day +2.31%
60-day +5.69%
120-day +9.2%
20-day
60-day
120-day
Win
58.8%
56.2%
56.2%
Sample
17
16
16
Median
+2.46%
+5.32%
+1.59%
Excess
+0.75%
+3.48%
+2.8%
Beat mkt rate
52.9%
56.2%
43.8%

Over 16 occurrences, 120-day forward avg gained 9.2%, beat the market by 2.8 pts; win rate 56.2%.

Top-quintile 6-month momentum

Active · now 96.26%

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

8 historical occurrences (since 2016-10-28)
Average forward return after Top-quintile 6-month momentum。20-day: Win 62.5%, Sample 8, Median +2.66%, Excess +4.88%, Beat mkt rate 62.5%；60-day: Win 57.1%, Sample 7, Median +1.03%, Excess -5.96%, Beat mkt rate 42.9%；120-day: Win 42.9%, Sample 7, Median -1.32%, Excess -2.46%, Beat mkt rate 42.9%

120 days after: historical avg +4.53%

20-day +4.61%
60-day -0.1%
120-day +4.53%
20-day
60-day
120-day
Win
62.5%
57.1%
42.9%
Sample
8
7
7
Median
+2.66%
+1.03%
-1.32%
Excess
+4.88%
-5.96%
-2.46%
Beat mkt rate
62.5%
42.9%
42.9%

Over 7 occurrences, 120-day forward avg gained 4.53%, lagged the market by 2.46 pts; win rate 42.9%.

Valuation regime and forward returns

Daily TTM P/E is converted into an expanding own-history percentile, then grouped into five valuation regimes. Forward returns use adjusted prices over the next 240 trading days.

PE percentile bandSample days240-day avg returnMedianWin rateAvg excess (vs index)
0-20 498+19.9% +8.7% 66.1% +13.9%
20-40 193+11.5% +15.3% 66.3% -4.5%
40-60 330-5.8% -4% 33.9% -26.5%
60-80 You are here33-27.1% -32.5% 0% -36.4%
80-100 0Insufficient data

Quarterly EPS is aligned by SEC filing date before it is forward-filled to daily prices. The expanding percentile uses only information available up to each day.

Current TTM P/E is about 59.37, placing it in the 73.5 own-history percentile, inside the 60-80 bucket.

More history: Valuation × momentum analogs, Market-wide momentum baseline, Signals not active now

Valuation × momentum analogs

Each historical day is grouped by own-history P/E tercile and 60-day momentum direction, then tested for the next 120-trading-day adjusted return.

Valuation
Momentum
Cheap (own-history bottom third)
Middle
Expensive (own-history top third)
60-day momentum up
+4%
Win rate 49.3% Excess +2.5%
349d
-1.5%
Win rate 49.7% Excess -10.6%
308d
Now
Insufficient data
(4d)
60-day momentum down
+13.5%
Win rate 60% Excess +9.8%
360d
+2.1%
Win rate 60.1% Excess -10.4%
153d
Insufficient data
(0d)

Days = trading days in this bucket; returns use adjusted prices, ex-costs. 60-day momentum: direction of this stock's price over the past 60 trading days.

Market-wide momentum baseline

Across 98,465 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.50%, a 58.4% positive-return rate, and +3.15 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

Filed revenue acceleration

Pending

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

EPS surprise beat

Pending

Reported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.

30 times historically; 60-day forward avg +5.23%, win rate 55.6%, beating the market by +2.7 pts on average.

Continue researching Haemonetics Corporation with the evidence above.

Continue in Studio ↗

Method and limits

  • Returns use us_price:adj_close, adjusted for splits and dividends where available.
  • Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
  • Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
  • The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
  • Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
  • Overlapping event windows are descriptive distributions, not independent samples.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.